Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, ...

BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...

Tech giant enhances its stunning design and the smoothest implementation of Android 16 with the addition of magnetic wireless ...

Last week, faculty and students signed a petition to oust the local Turning Point student chapter from Rutgers University.

AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage ...

AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...

AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain ...

AJ Dybantsa had 30 points, seven rebounds, three assists, three steals and a block, but Rienk Mast and Connor Essegian ...

Enhertu can help patients with breast cancer when given earlier in the disease, according to data presented at the ESMO ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...